Given the results of the GETUG 14 randomized trial presented at ASCO 2016, should all men with intermediate-risk prostate cancer receiving dose-escalated radiotherapy receive concurrent ADT?
In this abstract the 5-year probability of survival without clinical/biochemical relapse was significantly improved with ADT.
Community PollStarted
Do you recommend that all patients with intermediate-risk prostate cancer receive ADT with dose-escalated radiotherapy?
138 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet Member
Radiation Oncology · Brigham and Women's Hospital
Answered on
Neither the GETUG 14 or EORTC 22991 study just published in JCO are mature enough yet to fully answer the question based on endpoints of death from PC and/or overall survival.
The third study looking at this is RTOG 0815 which also is not mature yet.
It is likely that men with favorable int risk can b...
Join for free or sign in to see the full answer
Mednet Member
Radiation Oncology · IU Health/ Central Indiana Cancer Centers
Answered on
High dose radiation does not improve overall survival; ADT does improve OS . Why go beyond 7560cGy? It just dries up the prostate and decreases ejaculate.
Join for free or sign in to see the full answer